ArticleAntimicrobial agents and chemotherapy2018
UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria.
Erratum issuedAbstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Plasmodial Kinase Inhibitors Targeting Malaria: Recent Developments.Molecules (Basel, Switzerland) · 2020Pooled it
- Novel Inhibitors ofJournal of medicinal chemistry · 2025Article
- Characterization of the malaria parasiteMicrobiology spectrum · 2025Article
- Targeting Malaria's Achilles' Heels: A Review of Plasmodium Life Cycle Vulnerabilities for Drug Discovery.Current topics in medicinal chemistry · 2025Review
- To quest new targets ofJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2024Review
- Eliminating malaria transmission requires targeting immature and mature gametocytes through lipoidal uptake of antimalarials.Nature communications · 2024Article
- Dose-fractionation studies of aAntimicrobial agents and chemotherapy · 2024Article
- 2,8-Disubstituted-1,5-naphthyridines as Dual Inhibitors ofJournal of medicinal chemistry · 2024Article
- Antimalarial drug discovery: progress and approaches.Nature reviews. Drug discovery · 2023Review
- A Pyridyl-Furan Series Developed from the Open Global Health Library Block Red Blood Cell Invasion and Protein Trafficking inACS infectious diseases · 2023Article
- Predicting Optimal Antimalarial Drug Combinations from a Standardized Plasmodium falciparum Humanized Mouse Model.Antimicrobial agents and chemotherapy · 2023Article
- Beyond PI3Ks: targeting phosphoinositide kinases in disease.Nature reviews. Drug discovery · 2023Review
- The anticancer human mTOR inhibitor sapanisertib potently inhibits multipleScience translational medicine · 2022Article
- Innovation Experiences from Africa-Led Drug Discovery at the Holistic Drug Discovery and Development (H3D) Centre.ACS medicinal chemistry letters · 2022Article
- Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183.Nature communications · 2022Article
- PI4-kinase and PfCDPK7 signaling regulate phospholipid biosynthesis in Plasmodium falciparum.EMBO reports · 2022Article
- Longitudinal ex vivo and molecular trends of chloroquine and piperaquine activity against Plasmodium falciparum and P. vivax before and after introduction of artemisinin-based combination therapy in Papua, Indonesia.International journal for parasitology. Drugs and drug resistance · 2021Article
- Probing the distinct chemosensitivity of Plasmodium vivax liver stage parasites and demonstration of 8-aminoquinoline radical cure activity in vitro.Scientific reports · 2021Article
- Next-Generation Human Liver Models for Antimalarial Drug Assays.Antibiotics (Basel, Switzerland) · 2021Review
- Review
Corrections and comments
- Erratum issued
Authors and funding
48 authors.
Christel BrunschwigDrug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa.ORCID 0000-0003-2397-3174
Nina LawrenceDrug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa.
Dale TaylorDrug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa.
Efrem AbayDrug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa.
Mathew NjorogeDrug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa.
Gregory S BasarabDrug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa.
Claire Le ManachDrug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, South Africa.
Tanya PaquetDrug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, South Africa.
Diego Gonzàlez CabreraDrug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, South Africa.
Aloysius T NchindaDrug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, South Africa.
Carmen de KockDrug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa.
Lubbe WiesnerDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa.
Paolo DentiDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa.
David WatersonMedicines for Malaria Venture, Geneva, Switzerland.
Benjamin BlascoMedicines for Malaria Venture, Geneva, Switzerland.
Didier LeroyMedicines for Malaria Venture, Geneva, Switzerland.
Michael J WittyMedicines for Malaria Venture, Geneva, Switzerland.
Cristina DoniniMedicines for Malaria Venture, Geneva, Switzerland.
James DuffyMedicines for Malaria Venture, Geneva, Switzerland.
Sergio WittlinSwiss Tropical and Public Health Institute, Basel, Switzerland.
Karen L WhiteCentre for Drug Candidate Optimisation, Monash University, Melbourne, Victoria, Australia.
Susan A CharmanCentre for Drug Candidate Optimisation, Monash University, Melbourne, Victoria, Australia.
Maria Belén Jiménez-DíazGlaxoSmithKline, Tres Cantos Medicines Development Campus, Madrid, Spain.
Iñigo Angulo-BarturenGlaxoSmithKline, Tres Cantos Medicines Development Campus, Madrid, Spain.
Esperanza HerrerosGlaxoSmithKline, Tres Cantos Medicines Development Campus, Madrid, Spain.
Francisco Javier GamoGlaxoSmithKline, Tres Cantos Medicines Development Campus, Madrid, Spain.
Rosemary RochfordDepartment of Immunology and Microbiology, University of Colorado, Aurora, Colorado, USA.
Dalu MancamaBiosciences, Council for Scientific and Industrial Research, Pretoria, South Africa.
Theresa L CoetzerPlasmodium Molecular Research Unit, Wits Research Institute for Malaria, Department of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa.
Mariëtte E van der WattDepartment of Biochemistry, Institute for Sustainable Malaria Control and South African Medical Research Council Collaborating Centre for Malaria Research, University of Pretoria, Pretoria, South Africa.
Janette ReaderDepartment of Biochemistry, Institute for Sustainable Malaria Control and South African Medical Research Council Collaborating Centre for Malaria Research, University of Pretoria, Pretoria, South Africa.
Lyn-Marie BirkholtzDepartment of Biochemistry, Institute for Sustainable Malaria Control and South African Medical Research Council Collaborating Centre for Malaria Research, University of Pretoria, Pretoria, South Africa.
Kennan C MarshAbbVie, North Chicago, Illinois, USA.
Suresh M SolapureNagarjuna Gardens, Bangalore, India.
John E BurkeDepartment of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada.
Jacob A McPhailDepartment of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada.
Manu VanaerschotDepartment of Microbiology and Immunology, Columbia University Medical Center, New York, New York, USA.
David A FidockDepartment of Microbiology and Immunology, Columbia University Medical Center, New York, New York, USA.
Paul V FishAlzheimer's Research UK UCL Drug Discovery Institute, Faculty of Brain Sciences, University College London, London, United Kingdom.
Peter SieglSiegl Pharma Consulting LLC, Blue Bell, Pennsylvania, USA.
Dennis A SmithIndependent Researcher, Walmer, Kent, United Kingdom.
Grennady WirjanataGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia.
Rintis NoviyantiEijkman Institute for Molecular Biology, Jakarta, Indonesia.
Ric N PriceGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia.
Jutta MarfurtGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia.
Kigbafori D SilueCentre Suisse de Recherches Scientifiques en Côte d'Ivoire, Abidjan, Côte d'Ivoire.
Leslie J StreetDrug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, South Africa.
Kelly ChibaleDrug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, South Africa kelly.chibale@uct.ac.za.
Funding
Defining P. falciparum resistance to artemisinin-based combination therapiesR01AI109023 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FIDOCK, DAVID A · 2014 to 2025
$4.4MDefining the targets of broad intervention antimalarial agentsR01AI103058 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WINZELER, ELIZABETH A · 2013 to 2016
$2.6MNIAID NIH HHS R01 AI103058NIAID NIH HHS R01 AI109023Wellcome Trust 200909/Z/16/Z
Abstract
The 2-aminopyridine MMV048 was the first drug candidate inhibiting
Indexed as
1-phosphatidylinositol 4-kinase inhibitorabsorptiondistribution metabolismdrug discoveryexcretionhuman dose predictionin vivo efficacymalariapharmacokinetic/pharmacodynamic modelingpharmacokineticsPlasmodium spp.
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.